Complete Up To Date Information about Percorten -V.
NADA Number: 141-029 | |
| Proprietary Name |
Percorten®-V |
|---|---|
| Sponsor |
Novartis Animal Health US, Inc. |
| Sponsor Address |
3200 Northline Ave, Suite 300 Greensboro, NC 27408 USA |
| Ingredients |
Desoxycorticosterone Pivalate |
| Species |
Dog, restricted during pregnancy |
| Routes of Administration |
Intramuscular |
| Dose Form |
Liquid (suspension) |
| Drug Form |
Liquid (suspension) |
| Dispensing Status |
RX |
| Exclusivity |
Granted for use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency. |
|
Dosage Amount, Indications & Limitations |
522.535 Desoxycorticosterone pivalate. Specifications: Each milliliter of sterile aqueous suspension contains 25 milligrams of desoxycorticosterone pivalate. Conditions of use: Dogs Amount: Dosage requirements are variable and must be individualized on the basis of the response of the patient to therapy. Initial dose of 1 milligram per pound (0.45 kilogram) of body weight every 25 days, intramuscularly. Usual dose is 0.75 to 1.0 milligram per pound of body weight every 21 to 30 days. Indications: For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency. Limitations: For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian. |